32 results about "Vulvovaginal Candidiasis" patented technology

The present invention generally relates to methods and compositions for treating pathogenic vaginal biofilms. More specifically, the invention relates to pharmaceutical compositions comprising a combination of boric acid and diethylaminetetracetic acid (EDTA) and to methods of using such compositions to treat or prevent biofilm formation associated with vaginal infections, such as bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), trichomoniasis or mixed infections.

A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5 - 40%, b) at least one cellulose ether in preferred amounts of 30 - 90% and c) at least one disintegrant in preferred amounts of 2 - 50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. The matrix is used in solid formulations in amounts of about 5 - 60%, preferably 20-40%, and the active principle in amounts of about 2- 70 %, preferably 5-50% with respect to the weight of the formulation.

Methods and compositions for detection of vulvovaginal candidiasis (VVC), trichomoniasis and bacterial vaginosis (BV) are disclosed herein. In some embodiments, the presence or absence of VVC-associated Candida, Trichomonas vaginalis, and a plurality of BV-related bacteria in a sample is determined using multiplex nucleic acid-based testing methods.

The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.

The invention relates to use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders. A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. The matrix is used in amounts of about 5-60%, preferably 20-40%, and the active principle in amounts of about 2-70%, preferably 5-50%, with respect to the weight of the formulation.

In one embodiment, the invention provides a method for detecting increased risk of vulvovaginal candidiasis or vulvur vestibulitis syndrome. The method comprises obtaining a biological sample and determining whether a mutant allele of mannose-binding lectin gene is present in the sample. In another embodiment, the invention provides a method for treating or preventing vulvovaginal candidiasis or vulvur vestibulitis syndrome in a female in need thereof. The method comprises administering an effective amount of a mannose-binding lectin protein.

The invention discloses a Chinese herbal composition for treating tinea pedis and vulvovaginal candidiasis. The Chinese herbal composition consists of active ingredients and medically acceptable auxiliary materials, wherein the active ingredients are aqueous extracts prepared from the following raw materials including, by weight, 19-21 parts of cloves, 15-17 parts of patchouli, 19-21 parts of rhizoma coptidis, 14-16 parts of radix geutianae, 14-16 parts of radix stemonae, 2-4 parts of dried alum, 9-11 parts of mint and 0.5-1.5 parts of borneol. The herbal composition can be a lotion or a suppository or a cream for external use. It is proved by clinical verification that the herbal composition has the advantages of being accurate in treatment effect, capable of rapidly relieving symptoms and high in safety.

The invention discloses a medicinal composition for treating vulvovaginal candidiasis. The composition comprises 0.02 to 0.5 weight percent of Silaipufa peptide or pharmaceutically acceptable salt or ester, and pharmaceutically acceptable excipient and / or carrier. The invention also provides application of the Silaipufa peptide or pharmaceutically acceptable salt or ester in preparation of a medicament for treating the vulvovaginal candidiasis. The Silaipufa peptide can effectively inhibit the activity of candida albicans in vivo and in vitro, is used for local delivery of vulva, can effectively treat the vulvovaginal candidiasis, does not have side effect, and has a broad application prospect.

A method for treating vulvovaginal candidiasis including the steps of: (a) administering a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier intra-vaginally; and (b) applying miconazole nitrate in a pharmaceutically acceptable carrier to the vulva. Also a kit for the treatment of vulvovaginal candidiasis including: (a) a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier and in a form adapted to be administered intra-vaginally; and (b) an amount of miconazole nitrate in a pharmaceutically acceptable carrier adapted to be applied topically to the vulva.

The invention discloses a drug for treating relapsable vulvovaginal candidiasis, which is prepared by mixing 30-80ml of fluconazole with the following medicinal components in parts by weight: 2-4 parts of ketoconazole or 2-4 parts of itraconazole, 2-4 parts of metronidazole, 4-6 parts of lactein, 10-30 parts of calcined borax, 10-30 parts of golden cypress, 10-30 parts of coptis, 10-30 parts of vietnamese sophora root, 10-30 parts of borneol and 10-30 parts of mint. In the invention, western medicines and natural traditional Chinese medicines which are sensitive to the relapsable vulvovaginalcandidiasis are used as raw materials for treatment, and the drug disclosed by the invention has no toxicity and side effect, and is safe and durable. The drug disclosed by the invention has the advantages of remarkable curative effect, high cure rate, low relapse rate, short course and no drug dependence, can treat both principle and secondary aspect of disease, and is economical and efficient; and the used instrument is simple and low in toxicity and side effect.

The invention relates to a medicament for treating candidal vulvovaginitis in a birth control room. The medicament is prepared from following compounds by weight: 10-20 parts of psychotria calocarpa kurz, 5-15 parts of common calanthe herb, 10-20 parts of dwarf sheareria herb, 10-20 parts of pittosporum daphniphylloides hayata, 1-10 parts of semen iridis chinensis, 20-30 parts of oriental dodartia herb, 1-10 parts of tetragonal crotalaria herb, 5-15 parts of ceylon persimmon sawdust, 10-20 parts of largeleaf tea, 1-10 parts of myricaria bracteata royle, 20-30 parts of negundo chastetree leaf, 10-20 parts of nanocnide pilosa migo, 5-15 parts of ardisia brevicaulis diels, 10-20 parts of siebold knotweed fruit or herb, 20-30 parts of cuneate lespedeza herb with root, 5-15 parts of glabrous crazyweed herb, 5-15 parts of pansy, 20-30 parts of Indian pentanema herb, 5-15 parts of asiatic bilberry and 1-10 parts of licorice. The medicament has obvious curative effects for treating the candidal vulvovaginitis, and is simple and convenient in operation, safe to use, low in side and toxic effects, prone to popularization in clinic, and easily accepted by patients.

The present invention relates to a secnidazole vaginal expansion suppository and its preparation method and detection method; the expansion suppository comprises secnidazole, a matrix and an expansion carrier, and the drug-containing matrix of the expansion suppository contains triethanolamine oleate Can increase the dispersion uniformity of secnidazole in matrix, improve the bioavailability of suppository; Described thyme oil can improve the lubricity of suppository and the dissolution rate of active ingredient secnidazole, increase the human body's to secnidazole The absorption of azole, improve the bioavailability of suppository; Described dextran can improve the treatment of suppository vulvovaginal candidiasis, promote the healing of erosion, ulcer, improve the immunity of human body; Described dextran can also promote suppository forming, improving the stability of the suppository; the secnidazole vaginal expansion suppository is a hollow double-layer expansion suppository, and the drug-containing matrix is ​​wrapped in the matrix layer, so that the suppository of the present invention is more stable than ordinary suppositories; and the The secnidazole vaginal expansion suppository adopts six original leading technologies, which have beneficial effects such as preventing the outflow of medicinal liquid, high stability, and remarkable curative effect.

The disclosure includes compositions, kits, and methods for detecting and identifying vaginal disorders, such as vulvovaginal candidiasis, trichomoniasis, and / or bacterial vaginosis, based on nucleic acids. The compositions, kits, and methods are useful for obtaining robust diagnostic test performance against interfering substances, such as gels present in clinical vaginal swab samples.

The invention discloses a traditional Chinese medicine composition for treating tinea pedis and vulvovaginal candidiasis. The traditional Chinese medicinal composition is composed of active ingredients and medically acceptable auxiliary materials, wherein the active ingredients are prepared from the following raw materials in parts by weight Aqueous extracts: 19-21 parts of cloves, 15-17 parts of patchouli, 19-21 parts of Coptis chinensis, 14-16 parts of gentian, 14-16 parts of 100 parts, 2-4 parts of kale, 9-11 parts of mint 0.5‑1.5 servings of borneol. The medicine of the present invention can be three kinds of external preparations of lotion, suppository or cream, and has the advantages of precise curative effect, rapid symptom relief and good safety through clinical verification.

The invention discloses a coptis chinensis total alkaloid vaginal suppository, which is prepared by mixing of the following raw materials by mass: 6%-24% of coptis chinensis alkaloid, and 76%-94% of matrix. And the pH is controlled at 3.8-5.0. Further, the coptis chinensis total alkaloid vaginal suppository is an adhesive suppository, and is prepared by mixing of the following raw materials by mass: 3%-12% of coptis chinensis total alkaloid, 1%-4% of osthole, 1%-4% of aloe polysaccharide, 1%-4% of Hedyotis diffusa total flavone, 1-16% of a bioadhesive agent, and 60%-93% of matrix. The coptis chinensis total alkaloid vaginal suppository is for local medication, the efficacy is concentrated at a part of vagina, thus avoiding the first pass effect and liver, kidney toxicity caused by oral medication, extending the retention time of drug in vagina, at the same time solving the increasingly serious drug resistance and high recurrence rate problems caused by chemical drugs in VVC (vulvovaginal candidiasis) and RVVC (recurrent vulvovaginal candidiasis) treatment, and achieving the purpose of improving the treatment effect.

The invention relates to a Zhimikang expandable vaginal suppository. The expandable suppository comprises a traditional Chinese medicine composition, a matrix and an expansion carrier. The traditional Chinese medicine composition and the matrix form a drug-containing matrix, which is coated on the surface of the carrier. The traditional Chinese medicine composition is prepared from golden cypress, sophora flavescens, catechu, dried alum and borneol. bulk drugs including cortex lycii and gentian are further required for preparation of the traditional Chinese medicine composition, and can improve treatment effect of the expandable vaginal suppository on cervical erosion and vulvovaginal candidiasis; and the traditional Chinese medicine composition is prepared into microcapsules to increase the solubility and stability of the traditional Chinese medicine composition and increase bioavailability of the suppository. The Zhimikang expandable vaginal suppository employs seven unique technologies, and has beneficial effects of prevention of outflow liquid, high stability, lasting curative effect and prevention of secondary infection.